XIth Eurasian Hematology-Oncology Congress - EHOC 2020

 

XIth Eurasian Hematology-Oncology Congress - EHOC 2020
C

Recommendations for Treatment Discontinuation in CML: Is TFR Feasible? How Often to Monitor? What to Do After Early/Late Relapse?

By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Carmen Fava
By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Carmen Fava
0 views
January 12, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
Leukemia
18:13
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Pre-Pandemic CML Treatment: What Is CGA? How Do Ponatinib, Nilotinib…

Feat. P. Raanani
19:37
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Challenges in Treatment of Leukemias and Bone Marrow Failure in Deve…

Feat. K. Rashid
23:29
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

AML Treatment in Developing Countries: LIMC vs. HIC Differences - St…

Feat. E. Rego
15:57
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Cytogenetic Characterization in AML: How Do Gene Mutations Impact Ov…

Feat. M. Yilmaz
35:51
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Targeted Therapy for Older Patients With AML: Is Addition of GO to I…

Feat. C. Schiffer
18:11
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

State of the Art in Adults With ALL: Salvage & 1L Ino and Blina …

Feat. E. Jabbour
14:29
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

How I Manage CML at MD Anderson in 2020: Are 1L Therapies Getting Be…

Feat. E. Jabbour
17:01
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Pediatric ALL Updates: What Is the COG Risk Stratification Approach?…

Feat. S. Anak
16:00
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

ALL Highlights: Should We De-Escalate Chemo? Do TKIs (Dasatinib, Nil…

Feat. D. Hoelzer
23:41
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Ph+ and Ph-Like Adult Frontline ALL: What Is the Optimal Strategy in…

Feat. R. Foa
19:05
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

CAR-T in Pediatric ALL: Tisagenlecleucel in B-Cell Disease, CAR-T vs…

Feat. F. Saglio
30:27
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

CML Highlights: Has Molecular Monitoring Replaced Cytogenetic Monito…

Feat. R. Hehlmann
28:52
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Molecular Monitoring and CML: What Is the Influence on Therapy and H…

Feat. N. Chaudhri
31:57
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Recommendations for Treatment Discontinuation in CML: Is TFR Feasibl…

Feat. C. Fava
11:53
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

CML Updates: Prognostic Factors, Conventional Drugs, 1L Therapy, Tre…

Feat. W. Sattar
12:50
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

19 y/o Male With Jaundice and a Duodenal Ampulla Tumor: Does Standar…

Feat. M. Merter
15:31
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

AML Updates: Can CC-486 Improve OS in 1st Remission in Older Patient…

Feat. G. Garcia-Manero
20:42
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

AML Highlights: Do Gilteritinib & Quizartinib Prolong OS in FLT3…

Feat. G. Martinelli